Protypia analyzes the protein targets of oncology drugs and the protein pathways and networks in which they function. We use new mass spectrometry technology to quantitatively and precisely measure proteins. Protypia works with pharmaceutical and biotechnology companies from discovery through clinical trials. Our analyses quantify drug targets in preclinical models and human tumor tissue specimens, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. Our bioinformatics platforms translate our data to practically useful biological interpretation.

We partner with client teams to analyze drug targets and identify protein features—proteotypes—that indicate drug susceptibility and system response. We also analyze FFPE tissues from completed clinical trials to retrospectively identify proteotypes associated with trial outcomes, thereby informing the design of future trials. Protypia can collaborate in clinical trial design to reduce the risk of expensive trial failures.